Sign in
Taking people in United StatesPhase 2

JNJ-101556143 for Advanced Prostate Cancer That No Longer Responds to Hormone Therapy

Tests JNJ-101556143 in adults whose spread prostate cancer has stopped responding to hormone therapy.

Key facts

Who runs it
Janssen Research & Development, LLC
Where
Carmel, Chicago Ridge, Germantown, Lafayette, Largo, Plymouth, and Syracuse, United StatesSee the 7 sitesAlso in 3 other countries, 7 sites
Trial code
Registry title
A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer
Status
Recruiting
Phase
Phase 2
People taking part
100 people, planned
Started
16 Sept 2026
Expected to end
20 May 2030
Type of study
Interventional
Treatments tested
  • JNJ-101556143
Record updated
3 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with prostate cancer that has spread and has stopped responding to hormone therapy.

Age
18 years or older
Sex
Men only
Disease stage
Prostate cancer (adenocarcinoma) that has spread and is getting worse despite hormone therapy (mAPMR), with PSA of 10 ng/mL or higher and rising PSA or new or growing tumours on scans. Small cell, neuroendocrine and sarcoma types of prostate cancer cannot join.
Earlier treatment
Must be on continuing hormone-lowering treatment (ADT) or have had both testicles removed, with testosterone below 50 ng/dL. Must have stopped other cancer treatments: 2 weeks for chemotherapy, ARPI or radiation, 6 weeks for 177Lu PSMA-617, and 3 months for investigational drugs. Side effects of earlier treatment must have eased to Grade 1 or better.
Biomarker or test result
PSA of 10 ng/mL or higher. In Part 1, tumours that can be measured on scans (CT or MRI) and/or bone scan.

Main reasons for not taking part

  • Uncontrolled kidney disease, pancreatitis or liver disease (some exceptions)
  • Known allergy to JNJ-101556143 or its ingredients
  • Major surgery or serious injury within 28 days before the first dose
  • Spinal cord compression, unless treated and stable for 28 days
  • Solid organ or bone marrow transplant

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Have histologically confirmed adenocarcinoma of the prostate. Primary (or pathologic evidence of conversion to) small cell carcinoma, carcinoid tumor, mixed neuroendocrine carcinoma, large cell neuroendocrine carcinoma, or sarcoma of the prostate is disallowed
  • Progressive metastatic androgen pathway modulation-resistant prostate cancer (mAPMR) defined as having a Prostate-Specific Antigen (PSA) level greater than or equal (>=) 10 nanograms per milliliter (ng/mL) and at least one of the following: (a) PSA progression defined as at least 2 consecutive increases in PSA value over a previous reference value measured at least 1 week apart. (b) Progressive disease or new lesion(s) in the lymph nodes, bones, or viscera on conventional imaging (computed tomography [CT]/magnetic resonance imaging [MRI]) as defined by response evaluation criteria in solid tumors version 1.1 (RECIST v1.1) and/or on bone scan per Prostate Cancer Working Group 4 (PCWG4) while on Androgen Deprivation Therapy (ADT) (either surgically [bilateral orchiectomy] or with medication). Local-regional disease including invasive disease of rectum, bladder, pelvis is allowed as long as participant has a current or past history of distant metastasis (M1 disease). Participants in Part 1 must have measurable disease per RECIST v1.1 by conventional imaging with CT or MRI (chest, abdomen, and pelvis) and/or Technetium-99\^m (99\^mTc) bone scan confirmed by Blinded Independent Central Review (BICR) at the time of screening
  • Prior bilateral orchiectomy or medical castration (receiving ongoing ADT with a Gonadotropin-Releasing Hormone (GnRH) analog [agonist or antagonist]) with castrate level of serum testosterone (less than [<] 50 nanograms per deciliter [ng/dL] or 1.7 nanomoles per liter [nmol/L]) prior to the first dose of trial intervention and must continue this therapy throughout the treatment phase
  • Have discontinued concurrent use of any non-investigational systemic anticancer therapy (that is, cytotoxic chemotherapy, Androgen Receptor Pathway Inhibitor (ARPI), radiation therapy) within 2 weeks or Lutetium-177 Prostate-Specific Membrane Antigen-617 (177\^Lu PSMA-617) within 6 weeks prior to first dose of trial intervention, or any investigational drugs within 3 months of first dose of trial intervention
  • Toxicity related to prior anticancer treatment that is deemed clinically relevant must have resolved to common terminology criteria for adverse events (CTCAE) Version 6.0 Grade 1 or better

Who cannot take part

  • Had major surgery or had significant traumatic injury less than or equal to 28 days of the first dose of trial intervention. Note: Participants with planned surgical procedures to be conducted under local anesthesia may participate
  • Spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days
  • Solid organ or bone marrow transplantation
  • Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease (with exception of patients with Gilbert's Syndrome, asymptomatic gallstones, liver metastases, or stable chronic liver disease per investigator assessment)
  • Suspected or known allergies, hypersensitivity, or intolerance to JNJ-101556143 or its excipients

Where in United States

Also in 3 other countries, 7 sites

  • Urology of IndianaCarmel, United StatesTaking people
  • Associated Urological SpecialistsChicago Ridge, United StatesTaking people
  • The Conrad Pearson ClinicGermantown, United StatesTaking people
  • Southern Urology LLCLafayette, United StatesTaking people
  • Advanced Urology InstituteLargo, United StatesTaking people
  • Greater Boston UrologyPlymouth, United StatesTaking people
  • Associated Medical ProfessionalsSyracuse, United StatesTaking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate how well JNJ-101556143 works in participants with metastatic androgen pathway modulation-resistant prostate cancer (mAPMR), an advanced form of prostate cancer that has spread and no longer responds to hormone therapy. The study will measure the overall response (tumor shrinkage or disappearance) following treatment with JNJ-101556143.

The group in the trial

  • JNJ-101556143Treatment being tested

    Participants will receive JNJ-101556143 orally once daily in a 28-day treatment cycle until confirmed radiographic progression by blinded independent central review (BICR) or unequivocal clinical progression, or any other protocol-defined discontinuation criteria is met.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 2, Open-label, Multicenter, Single-arm Trial of JNJ-101556143, an Androgen Receptor-targeted Regulated Induced Proximity Targeting Chimera (RIPTAC™) Therapeutic in Participants With Metastatic Androgen Pathway Modulation-Resistant Prostate Cancer
Plain-language title
JNJ-101556143 for Advanced Prostate Cancer That No Longer Responds to Hormone TherapyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
3 November 2026